SRG-514 / SURGE Therap - LARVOL DELTA

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: SURGE Therapeutics | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Apr 2026 | Trial primary completion date: Sep 2025 ➔ Apr 2026

Enrollment closed • First-in-human • Trial completion date • Trial primary completion date • Inflammatory Breast Cancer • Oncology • Solid Tumor

SURGE Therapeutics Completes Phase 1 Dosing of First-in-Category Intraoperative Immunotherapy and Prepares for Registrational Trial (Businesswire) - "The treatment was generally well tolerated in the Phase 1 dose-escalation study, and there were no treatment-related dose-limiting toxicities or treatment-related serious adverse events to date. Based on the data generated to date and discussions with the FDA, the company is preparing to advance SRG-514 directly into a registrational trial....The company expects to initiate a registrational trial of SRG-514 in triple-negative breast cancer this year, with potential expansion into additional breast cancer and solid tumor indications."

New P3 trial • Trial status • Triple Negative Breast Cancer

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: SURGE Therapeutics | N=18 ➔ 24

Enrollment change • Surgery • Breast Cancer • Oncology • Solid Tumor

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: SURGE Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Surgery • Breast Cancer • Oncology • Solid Tumor

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: SURGE Therapeutics

New P1 trial • Surgery • Breast Cancer • Oncology • Solid Tumor